Form 8-K Outlook Therapeutics, For: Aug 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
BTIG Downgrades Outlook Therapeutics Incs. (OTLK) to Neutral
August 30, 2023 9:22 AM EDTBTIG analyst Julian Harrison downgraded Outlook Therapeutics Incs. (NASDAQ: OTLK) from Buy to Neutral.
The analyst comments "Outlook could disrupt over half the ocular anti-VEGF injection market by volume (>3.5 million injections/yr in the US) with what could emerge as the first FDA-approved intravitreal formulation of bevacizumab. Compounded bevacizumab is currently... More
